Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Josting

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2000
Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study GroupM Sieber, U Rüffer, A Josting, et al.
Der Internist|February 28, 2003
[Current therapeutic strategies in Hodgkin lymphoma]S Ansén, M Sieber, K Wingbermühle, et al.
Blood|August 15, 2000
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study GroupA Josting, U Rueffer, J Franklin, et al.
Annals of Hematology|September 12, 2002
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)J-P Glossmann, A Josting, B Pfistner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?A Josting, M Reiser, U Rueffer, et al.
Pediatric Research|November 1, 1995
Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interleukin-6 production in response to cytokines and viral challengeD Dilloo, R Vöhringer, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2010
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesisM Scholz, A Engert, J Franklin, et al.
European Journal of Medical Research|December 18, 1995
Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosisP D Wickramanayake, C Scheid, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study GroupK Behringer, A Josting, P Schiller, et al.
Leukemia & Lymphoma|August 3, 2002
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factorsM Reiser, A Josting, M Soltani, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2000
Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study GroupM Sieber, U Rüffer, A Josting, et al.
Der Internist|February 28, 2003
[Current therapeutic strategies in Hodgkin lymphoma]S Ansén, M Sieber, K Wingbermühle, et al.
Blood|August 15, 2000
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study GroupA Josting, U Rueffer, J Franklin, et al.
Annals of Hematology|September 12, 2002
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)J-P Glossmann, A Josting, B Pfistner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?A Josting, M Reiser, U Rueffer, et al.
Pediatric Research|November 1, 1995
Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interleukin-6 production in response to cytokines and viral challengeD Dilloo, R Vöhringer, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2010
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesisM Scholz, A Engert, J Franklin, et al.
European Journal of Medical Research|December 18, 1995
Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosisP D Wickramanayake, C Scheid, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study GroupK Behringer, A Josting, P Schiller, et al.
Leukemia & Lymphoma|August 3, 2002
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factorsM Reiser, A Josting, M Soltani, et al.
Pageof 5